# Trulieve Cannabis Corp. (TCNNF) — Initiating Coverage

## The Hook

Trulieve Cannabis made $91.5 million in pretax income last year. Then it paid $208 million in income taxes. Read that again: a company that was profitable before taxes paid more than double its pretax earnings in taxes, turning a $91 million winner into a $116 million loser. The effective tax rate was 227 percent. Not 27 — two hundred and twenty-seven. That is what happens when your business is profitable but the IRS says you cannot deduct rent, salaries, or marketing because cannabis is still a Schedule I controlled substance. Section 280E of the tax code turned a company generating $1.18 billion in revenue, 60 percent gross margins, and $273 million in operating cash flow into a GAAP money-loser. Trulieve is not a struggling business. It is a highly profitable business wearing a $189-million-per-year tax penalty like an ankle bracelet.

The stock trades at $6.61 — a $1.17 billion market cap for a company doing $1.18 billion in revenue. Price-to-sales of 1.0x. Enterprise value to EBITDA of 3.4x — the cheapest of any Tier 1 cannabis operator. The average analyst price target is $15.09, implying 128 percent upside. Nobody on Wall Street covers this stock because it is stuck on the OTC market, and nobody on the OTC market understands the 280E math well enough to see the company hiding underneath the distortion.

## Company Snapshot

Trulieve Cannabis Corp. is a vertically integrated multi-state cannabis operator headquartered in Tallahassee, Florida. Founded by CEO Kim Rivers, the company operates 233 retail dispensaries across the United States with over 4 million square feet of cultivation and processing capacity. Its revenue is overwhelmingly retail — 94 percent of the $1.18 billion top line comes from dispensary sales, with the remaining 6 percent from wholesale. Florida remains the company's center of gravity, generating roughly 67 percent of total revenue. Trulieve also operates in Pennsylvania, Ohio, Maryland, Arizona, West Virginia, and several other states, with a conditional license recently won in Texas.

This analysis is based on Trulieve's 10-K filed February 26, 2026, covering fiscal year 2025.

## The Financial Story

**Revenue: $1.2 billion with no growth — but the context matters.** Trulieve reported $1.181 billion in revenue for FY2025, essentially flat versus $1.186 billion in FY2024. The headline looks like stagnation, but underneath it, management navigated several headwinds: pricing compression across mature cannabis markets, the fallout from Florida's failed recreational ballot in November 2024 (which Trulieve spent $66 million supporting through campaign contributions), and softer consumer spending. Traffic and units sold were both up 5 percent year-over-year, and wholesale revenue grew 23 percent to a record $71 million, driven by Maryland and Pennsylvania. Trulieve also sold over 50 million branded product units. The top line held despite real headwinds — a sign of the operational machine underneath.

For context, the revenue trajectory peaks in FY2022 at $1.218 billion, dipped to $1.129 billion in FY2023 (the trough of the bust cycle), and recovered to the $1.18 billion range where it has now stabilized. This is a company that survived the cannabis bust without revenue collapsing — a rarity in the sector.

**Margins: Best in class and it is not close.** The 60 percent gross margin is the headline metric that separates Trulieve from every other MSO. Green Thumb runs about 52 percent. Curaleaf runs about 50 percent adjusted. Trulieve's margin reflects its vertically integrated Florida operation — growing, processing, and selling through its own dispensaries — combined with scale-driven cost efficiencies and disciplined promotional management. Adjusted SG&A declined to 30 percent of revenue from 31 percent the prior year. The result is record adjusted EBITDA of $427 million at a 36 percent margin, up from $420 million the year before.

**The 280E distortion makes GAAP earnings meaningless.** This is the single most important thing to understand about Trulieve's financials. Operating income was $143.5 million in FY2025 — the company is profitable at an operating level. Pretax income from continuing operations was $91.5 million. But the income tax provision was $208 million, creating a GAAP net loss of $116 million. The reason is Section 280E, which prevents cannabis companies from deducting ordinary business expenses (rent, salaries, marketing, utilities) because cannabis is a Schedule I substance. Only cost of goods sold is deductible. The result is that the tax is computed on gross income rather than net income, producing effective tax rates that are surreal: 82.7 percent in FY2021, negative 849 percent in FY2022 (when the company had pretax losses but still owed taxes), and 227 percent in FY2025.

The 280E penalty in dollar terms: $208 million in taxes on $91.5 million pretax income, versus roughly $19 million if taxed at a normal 21 percent rate. That is $189 million per year in excess tax. Put differently: without 280E, Trulieve's FY2025 net income would have been approximately $72 million positive. The company itself confirmed this — management stated on the earnings call that excluding the impact of 280E, full year results would reflect positive net income.

Trulieve has taken the most aggressive stance in the industry on 280E. Beginning in 2019, they filed amended federal returns challenging 280E's applicability, and to date they have received $114 million in refund checks from the IRS. They carry a $668 million uncertain tax position on the balance sheet, of which $630 million relates to the 280E challenge. Management says they do not believe the company will ever pay that amount.

**Cash flow tells the real story.** Operating cash flow was a record $273 million in FY2025, up from $271 million the prior year. Free cash flow was a record $229 million, up from $149 million. Capital expenditure dropped to $44 million from $123 million as the company shifted from build-out mode to harvest mode. Cash taxes paid were only $1.5 million in FY2025 (compared to receiving $48 million in net refunds in FY2024) — a direct result of Trulieve's aggressive 280E challenge strategy. This is a cash flow machine: $229 million in free cash flow on a $1.17 billion market cap is a 19.6 percent free cash flow yield. That is extraordinary for any company, let alone one in an industry with zero institutional coverage.

**Debt: cleaned up and manageable.** In December 2025, Trulieve redeemed $368 million in senior secured notes due 2026 and repaid a $15.8 million mortgage. To fund this, they issued $140 million in new senior secured notes due 2030 at 10.5 percent. The company ended the year with $256 million in cash and $232 million in total debt. Post-period, they raised an additional $60 million through a second private placement at 10.5 percent due 2030. With $273 million in annual operating cash flow against $232 million in debt, the balance sheet is clean. Interest expense was $63.5 million in FY2025, roughly 5.4 percent of revenue — elevated but serviceable.

**Goodwill and impairments: the boom-era scars.** Trulieve carries $484 million in goodwill and $798 million in finite-lived intangible assets on its balance sheet. Together, that is $1.28 billion — nearly half of total assets of $2.7 billion. The company took massive impairments in FY2023 (which contributed to the $527 million net loss that year) as boom-era acquisition values were written down. In FY2025, goodwill impairments were zero, suggesting the write-down cycle may be over. But the remaining goodwill as a percentage of total assets is 18 percent — still a meaningful risk if market conditions deteriorate further.

## Catalyst Scenarios — How the Math Changes

**280E Relief: the transformation.** Take Trulieve's actual FY2025 pretax income of $91.5 million. Apply a normal 21 percent corporate tax rate: $19.2 million in tax. Net income: $72.3 million. Divide by 192.3 million shares outstanding: pro-forma earnings per share of approximately $0.38. At the current stock price of $6.61, that implies a price-to-earnings ratio of about 17.4 times adjusted earnings. For a company with 60 percent gross margins, $427 million in adjusted EBITDA, and $229 million in free cash flow, 17.4 times earnings is not expensive — it is a consumer staples multiple on a company growing its branded product portfolio and retail footprint. The stock is currently priced as if 280E relief will never happen. If it does, the valuation re-rates mechanically.

But the math gets better. If 280E goes away, it does not just fix the tax line — it eliminates the $189 million annual cash drain on the business. That cash can be redeployed into growth (Texas build-out, new dispensaries, M&A), returned to shareholders, or used to further reduce debt. And the UTP liability — $668 million on the balance sheet — would begin to resolve, potentially releasing capital and removing an overhang.

**Interstate commerce (Bondi memo scenario): Trulieve is built for it.** If AG Bondi issues enforcement guidance permitting interstate cannabis commerce, Trulieve is among the best-positioned MSOs. The company has over 4 million square feet of cultivation capacity — primarily in Florida, a low-cost production state with year-round growing season. It has 233 retail locations across multiple states. And it has an established branded product portfolio (Modern Flower, Roll One) with 50 million units sold annually. The ability to ship Florida-grown product to dispensaries in Pennsylvania, Ohio, and other states would collapse the inefficiency of state-by-state vertical integration. Trulieve's Florida cultivation asset goes from a single-state engine to a national production hub overnight.

**Consolidation: buyer, not target.** With $256 million in cash (plus $60 million raised post-period), $229 million in annual free cash flow, and only $232 million in debt, Trulieve has balance sheet capacity to acquire. CEO Kim Rivers stated on the earnings call that "with valuations where they're at and where the market is, as well as our cash position, we are in a good spot to be inquisitive in the future." Enterprise value of $1.47 billion against $2.7 billion in assets means the company trades at roughly 0.54x book value — but the balance sheet strength makes it more likely a buyer than a target. Texas is the most immediate organic growth opportunity, with Rivers calling it "one of the most attractive market opportunities since Florida."

**Uplisting readiness: strong.** Trulieve has the financial profile that would attract institutional capital: billion-dollar revenue, 60 percent gross margins, record EBITDA, positive free cash flow, and a clean balance sheet. It already files 10-K reports with the SEC. If rescheduling clears the way for NYSE or NASDAQ listing, Trulieve is among the first MSOs that would qualify. The step-up in liquidity and institutional access could drive significant multiple expansion from current depressed levels.

## Risks and Open Questions

The biggest risk is Florida concentration. Approximately 67 percent of Trulieve's revenue comes from one state. The recreational ballot failed in November 2024, and the company spent $66 million on the campaign — money that did not generate return. The campaign is attempting ballot inclusion for 2026 midterms, but the Florida Supreme Court must resolve a dispute over invalidated signatures. If Florida adult-use stalls again, Trulieve's growth story depends on Texas, Pennsylvania legislative action, and wholesale expansion in other states — none of which are guaranteed.

Rescheduling itself remains uncertain. Despite Trump's executive order in December 2025, cannabis is still Schedule I as of March 2026. The DEA has no judge, the AG has gone silent, and 48 Republican lawmakers publicly oppose rescheduling. The timeline could extend well beyond 2026. Meanwhile, the 280E burden continues — $189 million per year in excess taxes for Trulieve alone. Revenue is flat, and Q1 2026 guidance calls for a sequential decline. Without catalysts, this is a $6-7 stock generating strong cash flow but showing no GAAP earnings growth.

The $668 million uncertain tax position is a sword that cuts both ways. If Trulieve's 280E challenge ultimately fails at the IRS or in court, the company could face a significant tax liability — though the practical enforceability of a $668 million claim against a cannabis company in a post-rescheduling world is questionable.

## The Bottom Line

Trulieve is a $1.18 billion revenue company with 60 percent gross margins, $427 million in adjusted EBITDA, and $229 million in free cash flow — all hidden behind a 227 percent effective tax rate created by Section 280E. Strip the 280E distortion, and you get a company earning roughly $0.38 per share in pro-forma earnings, trading at about 17 times those earnings with a 19.6 percent free cash flow yield. It is the cheapest Tier 1 MSO on an EV-to-EBITDA basis at 3.4 times, with the strongest margins in the industry and a balance sheet that gives it optionality. The catalysts are real — rescheduling, 280E relief, interstate commerce, uplisting — but none are guaranteed. Watch the DEA rulemaking process, the Florida Supreme Court decision on the 2026 ballot, and the Texas license buildout. If the switch flips, the math here changes dramatically. If it does not, this remains a strong cash-generating business trapped behind a regulatory wall.